# Phase II Efficacy Study of AZD6244 in Colorectal Cancer

> **NCT00514761** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 64 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** AZD6244
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00514761
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2007-06
- **Final completion:** 2008-07
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2014-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00514761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00514761, "Phase II Efficacy Study of AZD6244 in Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00514761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*